A three-year follow-up study of psoriasis patients treated with low dosages of etretinate orally and corticosteroids topically.

Abstract

Etretinate 0.5 mg/kg body weight combined with 0.1% triamcinolone acetonide and 5% salicylic acid in an O/W cream gave more than 70% improvement in 62% of 75 patients. Of this satisfactorily improved group, at least 41% were still in the same condition after 3 years on a maintenance dose of, on average, 0.3 mg/kg body weight etretinate daily and 20 g weekly of a relatively strong corticosteroid cream. The side effects were acceptable and the convenience for the patients is great as compared with other treatment.

• Authors: M K Polano, H J van der Rhee, J G van der Schroeff
• Journal: Acta dermato-venereologica (Acta Derm Venereol) Vol. 62 Issue 4 Pg. 361-4 ( 1982) ISSN: 0001-5555 [Print] Sweden
• PMID: 6183880 (Publication Type: Journal Article)

Chemical References

• Tretinoin
• Etretinate

Topics

• Administration, Oral
• Administration, Topical
• Alopecia (chemically induced)
• Atrophy (chemically induced)
• Etretinate (administration & dosage, adverse effects, therapeutic use)
• Follow-Up Studies
• Humans
• Psoriasis (drug therapy)
• Skin (pathology)
• Tretinoin (analogs & derivatives)